Literature DB >> 28592423

Remission of Hematuria Improves Renal Survival in IgA Nephropathy.

Angel M Sevillano1, Eduardo Gutiérrez1, Claudia Yuste1, Teresa Cavero1, Evangelina Mérida1, Paola Rodríguez1, Ana García1, Enrique Morales1, Cristina Fernández2, Miguel Angel Martínez3, Juan Antonio Moreno4, Manuel Praga5,6.   

Abstract

Hematuria is a cardinal symptom in IgA nephropathy, but its influence on the risk of disease progression has been scarcely investigated. We followed a cohort of 112 patients with IgA nephropathy for a mean±SEM period of 14±10.2 years, during which clinical and analytic risk factors (including urine sediment examination) were regularly recorded. According to the magnitude of time-averaged hematuria, we classified patients as those with persistent hematuria and those with negative or minimal hematuria. We also classified patients according to the magnitude of time-averaged proteinuria (>0.75 or ≤0.75 g/d). The proportion of patients reaching ESRD or a 50% reduction of renal function was significantly greater among patients with persistent hematuria than patients with minimal or negative hematuria (30.4% and 37.0% versus 10.6% and 15.2%, respectively; P=0.01). Multivariable analysis revealed time-averaged hematuria, time-averaged proteinuria, renal function at baseline, and the presence of tubulointerstitial fibrosis on renal biopsy as independent predictors of ESRD. After hematuria disappearance, which occurred in 46% of the patients, the rate of renal function decline changed from -6.45±14.66 to -0.18±2.56 ml/min per 1.73 m2 per year (P=0.001). Patients with time-averaged proteinuria >0.75 g/d had significantly poorer renal survival than those with time-averaged proteinuria ≤0.75 g/d. However, on further classification by time-averaged hematuria, only those patients with time-averaged proteinuria >0.75 g/d and persistent hematuria had significantly worse renal survival than those in the other three groups. In conclusion, remission of hematuria may have a significant favorable effect on IgA nephropathy outcomes.
Copyright © 2017 by the American Society of Nephrology.

Entities:  

Keywords:  IgA nephropathy; hematuria; progression of renal failure; proteinuria

Mesh:

Year:  2017        PMID: 28592423      PMCID: PMC5619972          DOI: 10.1681/ASN.2017010108

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  35 in total

Review 1.  IgA nephropathy: recent developments.

Authors:  Jürgen Floege; John Feehally
Journal:  J Am Soc Nephrol       Date:  2000-12       Impact factor: 10.121

Review 2.  IgA nephropathy.

Authors:  Robert J Wyatt; Bruce A Julian
Journal:  N Engl J Med       Date:  2013-06-20       Impact factor: 91.245

3.  Prognostic relevance of clinical and histological features in IgA nephropathy treated with steroid and angiotensin receptor blockers.

Authors:  S Choi; D Lee; K-H Jeong; J-Y Moon; S H Lee; T-W Lee; C-G Ihm
Journal:  Clin Nephrol       Date:  2009-11       Impact factor: 0.975

4.  The MEST score provides earlier risk prediction in lgA nephropathy.

Authors:  Sean J Barbour; Gabriela Espino-Hernandez; Heather N Reich; Rosanna Coppo; Ian S D Roberts; John Feehally; Andrew M Herzenberg; Daniel C Cattran
Journal:  Kidney Int       Date:  2016-01       Impact factor: 10.612

Review 5.  The IgA nephropathy treatment dilemma.

Authors:  G B Appel; M Waldman
Journal:  Kidney Int       Date:  2006-06       Impact factor: 10.612

6.  Predicting progression in IgA nephropathy.

Authors:  L P Bartosik; G Lajoie; L Sugar; D C Cattran
Journal:  Am J Kidney Dis       Date:  2001-10       Impact factor: 8.860

Review 7.  Haematuria as a risk factor for chronic kidney disease progression in glomerular diseases: A review.

Authors:  Juan Antonio Moreno; Claudia Yuste; Eduardo Gutiérrez; Ángel M Sevillano; Alfonso Rubio-Navarro; Juan Manuel Amaro-Villalobos; Manuel Praga; Jesús Egido
Journal:  Pediatr Nephrol       Date:  2015-05-17       Impact factor: 3.714

8.  The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification.

Authors:  Daniel C Cattran; Rosanna Coppo; H Terence Cook; John Feehally; Ian S D Roberts; Stéphan Troyanov; Charles E Alpers; Alessandro Amore; Jonathan Barratt; Francois Berthoux; Stephen Bonsib; Jan A Bruijn; Vivette D'Agati; Giuseppe D'Amico; Steven Emancipator; Francesco Emma; Franco Ferrario; Fernando C Fervenza; Sandrine Florquin; Agnes Fogo; Colin C Geddes; Hermann-Josef Groene; Mark Haas; Andrew M Herzenberg; Prue A Hill; Ronald J Hogg; Stephen I Hsu; J Charles Jennette; Kensuke Joh; Bruce A Julian; Tetsuya Kawamura; Fernand M Lai; Chi Bon Leung; Lei-Shi Li; Philip K T Li; Zhi-Hong Liu; Bruce Mackinnon; Sergio Mezzano; F Paolo Schena; Yasuhiko Tomino; Patrick D Walker; Haiyan Wang; Jan J Weening; Nori Yoshikawa; Hong Zhang
Journal:  Kidney Int       Date:  2009-07-01       Impact factor: 10.612

9.  Remission of proteinuria improves prognosis in IgA nephropathy.

Authors:  Heather N Reich; Stéphan Troyanov; James W Scholey; Daniel C Cattran
Journal:  J Am Soc Nephrol       Date:  2007-10-31       Impact factor: 10.121

Review 10.  New developments in the genetics, pathogenesis, and therapy of IgA nephropathy.

Authors:  Riccardo Magistroni; Vivette D D'Agati; Gerald B Appel; Krzysztof Kiryluk
Journal:  Kidney Int       Date:  2015-09-16       Impact factor: 10.612

View more
  28 in total

1.  IgA nephropathy: is a new approach beyond proteinuria necessary?

Authors:  Eduardo Gutiérrez
Journal:  Pediatr Nephrol       Date:  2019-02-18       Impact factor: 3.714

2.  Persistent Microscopic Hematuria as a Risk Factor for Progression of IgA Nephropathy: New Floodlight on a Nearly Forgotten Biomarker.

Authors:  Rosanna Coppo; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2017-07-24       Impact factor: 10.121

Review 3.  The epipharynx-kidney axis triggers glomerular vasculitis in immunoglobulin A nephropathy.

Authors:  Osamu Hotta; Takashi Oda
Journal:  Immunol Res       Date:  2019-10       Impact factor: 2.829

4.  Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy.

Authors:  Aliza Thompson; Kevin Carroll; Lesley A Inker; Jürgen Floege; Vlado Perkovic; Sonia Boyer-Suavet; Rupert W Major; Judith I Schimpf; Jonathan Barratt; Daniel C Cattran; Barbara S Gillespie; Annamaria Kausz; Alex W Mercer; Heather N Reich; Brad H Rovin; Melissa West; Patrick H Nachman
Journal:  Clin J Am Soc Nephrol       Date:  2019-01-11       Impact factor: 8.237

5.  Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy.

Authors:  Thomas Rauen; Christina Fitzner; Frank Eitner; Claudia Sommerer; Martin Zeier; Britta Otte; Ulf Panzer; Harm Peters; Urs Benck; Peter R Mertens; Uwe Kuhlmann; Oliver Witzke; Oliver Gross; Volker Vielhauer; Johannes F E Mann; Ralf-Dieter Hilgers; Jürgen Floege
Journal:  J Am Soc Nephrol       Date:  2017-10-17       Impact factor: 10.121

6.  Effect of Cyclophosphamide and Glucocorticoid Therapy in IgA Nephropathy: A Single-Center Retrospective Analysis.

Authors:  Nicolas Beck; Gerd Walz; Johanna Schneider
Journal:  Kidney360       Date:  2022-01-19

Review 7.  An evaluation of the roles of hematuria and uric acid in defining the prognosis of patients with IgA nephropathy.

Authors:  Ron Hogg
Journal:  Pediatr Nephrol       Date:  2021-05-13       Impact factor: 3.714

Review 8.  Treatment of IgA nephropathy in children: a land without KDIGO guidance.

Authors:  Rosanna Coppo
Journal:  Pediatr Nephrol       Date:  2020-02-14       Impact factor: 3.714

9.  Persistent Disease Activity in Patients With Long-Standing Glomerular Disease.

Authors:  Elisa Delbarba; Maddalena Marasa; Pietro A Canetta; Stacy E Piva; Debanjana Chatterjee; Byum Hee Kil; Xueru Mu; Keisha L Gibson; Michelle A Hladunewich; Jonathan J Hogan; Bruce A Julian; Jason M Kidd; Louis-Philippe Laurin; Patrick H Nachman; Michelle N Rheault; Dana V Rizk; Neil S Sanghani; Howard Trachtman; Scott E Wenderfer; Ali G Gharavi; Andrew S Bomback
Journal:  Kidney Int Rep       Date:  2020-03-20

10.  Distribution of nephrologists and regional variation in the clinical severity of IgA nephropathy at biopsy diagnosis in Japan: a cross-sectional study.

Authors:  Yusuke Okabayashi; Nobuo Tsuboi; Hoichi Amano; Yoichi Miyazaki; Tetsuya Kawamura; Makoto Ogura; Ichiei Narita; Toshiharu Ninomiya; Hitoshi Yokoyama; Takashi Yokoo
Journal:  BMJ Open       Date:  2018-10-31       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.